| | GAITHERSBURG, Md., May 13, 2024 /PRNewswire/ -- Novavax Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will participate in the BofA Securities 2024 Health Care Conference. | Conference Details: | | | | Fireside Chat | | | Date: | Wednesday, May 15, 2024 | | Time: | 3:00 – 3:30 p.m. Pacific Daylight Time (PDT) | | Location: | Encore Hotel in Las Vegas, NV | | Moderator: | Alec Stranahan, PhD, Equity Research – U.S. Biopharma | | Novavax participant: | John C. Jacobs, President and Chief Executive Officer | | | | | Conference | | | Event: | Investor Meetings | | Date: | Wednesday, May 15, 2024 | Recordings
A replay of the recorded fireside session will be available through the Events & Presentations page of the Company’s website at ir.novavax.com for 30 days from the date of the conference. About Novavax
Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to help protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax’s patented Matrix-M adjuvant to enhance the immune response. The Company’s portfolio includes its COVID-19 vaccine and its pipeline includes COVID-19-Influenza Combination and stand-alone influenza vaccine candidates. In addition, Novavax’s adjuvant is included in the University of Oxford and Serum Institute of India’s R21/Matrix-M malaria vaccine. Please visit novavax.com and LinkedIn for more information. Contacts:
Investors
Erika Schultz
240-268-2022
ir@novavax.com Media
Giovanna Chandler
202-709-5563
media@novavax.com  View original content to download multimedia:https://www.prnewswire.com/news-releases/novavax-to-participate-in-bofa-securities-2024-health-care-conference-302143793.html
SOURCE Novavax, Inc. | |
